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Background: Altered levels of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of
metalloproteinases (TIMPs), are involved in cardiovascular alterations associated with end stage kidney dis-
ease (ESKD). Genetic polymorphisms in MMP-9 gene affect MMP-9 levels. We examined how MMP-9 poly-
morphisms and haplotypes affect the changes in plasma MMP-9 and TIMP-1 levels found in patients with
ESKD undergoing hemodialysis.
Methods: We studied 94 ESKD patients undergoing hemodialysis for at least 3 months. MMP-9 and TIMP-1
were measured by ELISA in plasma from blood samples collected before and after a session of hemodialysis.
Genotypes for three MMP-9 polymorphisms (C−1562T, rs3918242; −90 (CA)14–24, rs2234681; and Q279R,
rs17576) were determined by Taqman® Allele Discrimination Assay and real-time polymerase chain reac-
tion. Haplotype frequencies were determined with the software program PHASE 2.1.
Results: Hemodialysis increased MMP-9 and TIMP-1 levels (Pb0.05). Genotypes had no effects on baseline
MMP-9 and TIMP-1 levels (P>0.05). Hemodialysis increased MMP-9 and TIMP-1 levels in subjects with
the CC (but not CT or TT) genotype for the C−1562T polymorphism (Pb0.05), and increased MMP-9 levels
in subjects with the QQ (but not QR or RR) genotype for the Q279R polymorphism (Pb0.05), whereas the
CA(n)14–24 polymorphism had no major effects. While MMP-9 haplotypes had no effects on baseline
MMP-9 levels (P>0.05), hemodialysis increased MMP-9 levels andMMP-9/TIMP-1 ratios in subjects carrying
the CLQ haplotype (P=0.0012 and P=0.0045, respectively).
Conclusion: ESKD patients with the QQ genotype for the Q279R polymorphism or with the CLQ haplotype are
exposed to more severe increases in MMP-9 levels after hemodialysis. Such patients may beneﬁt from the use
of MMP inhibitors.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Patients with end stage kidney disease (ESKD) bear a heavy burden
of cardiovascular diseases (CVD) [1], and hemodialysis may trigger a
maladaptive process leading to arterial medial calciﬁcation, stiffness,
and loss of functionmimicking the atherogenic effects of uremic factors
and inﬂammation [1,2]. These vascular alterations found in ESKD are
linked to extracellular matrix remodeling and elastocalcinosis [2,3]
and involve imbalanced matrix metalloproteinase (MMP) activity [4].
MMPs are structurally related, zinc dependent, enzymes that
degrade the extracellular matrix and other non-extracellular matrix-ology, Faculty of Medicine of
tes, 3900 14049-900 Ribeirao
3633 2301.
ahoo.com (J.E. Tanus-Santos).
t.
evier OA license.related substrates [5]. They are regulated at transcriptional and
post-translational levels, and their activity is also dependent on
endogenous inhibitors, the tissue inhibitors of MMPs (TIMPs) [6].
Mounting evidence indicates that imbalancedMMP activity contributes
to diseased vessels in patients with renal failure [3,7–9], particularly
MMP-9,which is associatedwith atherosclerosis in non-dialytic chronic
kidney disease (CKD) [7,8]. Moreover, increasedMMP-9 expression has
been reported in monocytes from patients with ESKD [10], and recent
studies have shown altered MMP-9 and TIMP-1 levels in patients
on dialysis [11–15]. Nevertheless, inconsistent ﬁndings have been
reported regarding the effects of hemodialysis on the circulating MMP
levels. Some studies suggest that plasma MMP-9 remains unaltered
[11,12,16] or decreases after a hemodialysis session [13,17].
MMP-9 activity is highly dependent on its expression levels [6,18],
and functional genetic polymorphisms in the MMP-9 gene may affect
MMP-9 concentrations [19], possibly modifying the susceptibility to
cardiovascular diseases [18,20,21]. Therefore, we hypothesized that
47B.P. Marson et al. / Clinica Chimica Acta 414 (2012) 46–512 functional polymorphisms in the promoter region of MMP-9 gene
(the C−1562T — rs3918242, and the microsatellite (CA)14–24 in −90
position — rs2234681), and one polymorphism in exon 6 (the
Q279R; rs17576) could affect the changes in MMP-9 levels associated
with hemodialysis. In support of this hypothesis, these polymorphisms
have been associated with variable MMP-9 levels in other clinical
conditions [22–24]. While previous works have studied MMP-2 [25]
and MMP-9 [26] polymorphisms in dialysis, no previous study has
examined how functionalMMP-9polymorphisms, or their combinations
within haplotypes, affect the changes in MMP-9 and TIMP-1 levels
during a hemodialysis session.
2. Materials and methods
2.1. Patients
The present study was carried out in accordance with the Helsinki
Declaration ethical guidelines. Approval for use of human blood was
obtained from the Research Ethics Committee of the Pontíﬁcia
Universidade Católica do Rio Grande do Sul, and informed consent
was obtained from each participant. Ninety-four patients with ages
from 18 to 65 y were studied in 3 hemodialysis units. ESKD was
deﬁned as glomerular ﬁltration rate b15 ml/min associated with clin-
ical signs of uremic syndrome requiring dialysis. The patients were on
continuous therapy for at least 3 months and were stable (without
clinical complications). Clinical data were based on medical history,
physical examination, and routine analytical tests. While the patients
included in the present study had different causes for their clinical
condition, diabetes mellitus, hypertension, glomerulonephritis, and
polycystic kidney disease were the main causal diseases. The dialysis
schedule included three 4-h dialysis sessions per week with a
polysulfone hollow-ﬁber membrane, bicarbonate dialysate, and regular
heparin anticoagulation. Reverse osmosis was used for water treatment
and the dialysate was regularly checked for the presence of endotoxin.
Dialysis adequacy was evaluated by measuring Kt/V. Blood pressure
wasmeasured using a calibrated sphygmomanometerwith appropriated
cuff size.
Blood samples were collected into EDTA vaccutainer tubes
(Becton-Dickinson, São Paulo, Brazil) by venipuncture of the arterio-
venous ﬁstula before and after a hemodialysis session. The blood
samples were centrifuged at 1000×g for 10 min and plasma fractions
were immediately stored at −70 °C until used for biochemical
measurements. Blood samples were also collected to extract genomic
DNA. The biochemical and hematological parameters were determined
by routine techniques using an automated analyzer (Johnson Vitros
Chemistry 5.1 SS). LDL-cholesterol was calculated using the Friedewald's
formula.
2.2. Genotyping
Genotypes for the C−1562T (rs3918242) polymorphism in the
5′-ﬂanking region of MMP-9 were determined by polymerase chain
reaction (PCR) ampliﬁcation using the primers: 5′-GCCTGGCAC
ATAGTAGGCCC-3′ (sense) and 5-CTTCCTAGCCAGCCGGCATC-3
(antisense), and PCR conditions as described elsewhere [27]. The ampli-
ﬁed products were digested with SphI (New England Biolabs, Ipswich,
MA) overnight at 37 °C, producing fragments of 247 and 188 bp in the
case of a polymorphic variant (allele T), or an undigested 435-bp band
in the case of a wild type allele (allele C). Fragments were separated by
electrophoresis in 12% polyacrylamide gels and visualized after silver
staining.
The −90 (CA)14–24 (rs3222264) microsatellite was detected by
polymerase chain reaction as described previously [19], using the
primers 5′-GACTTGGCAGT GGAGACTGCGGGCA-3′ (sense) and 5′-GAC
CCCACCCCTCCTTGACAGGCAA-3′ (antisense). Ampliﬁed products were
separated in a 7% polyacrylamide–urea gel and visualized after silverstaining. Differences in molecular weight (or number of bases), from
144 bp to 168 bp, were determined by a comparison with migration
of a 10-bp DNA ladder (Invitrogen, Carlsbad, CA) and to homozygous
samples previously sequenced. In order to make easier the analysis of
the bands in the gel, the alleles were classiﬁed in accordance with the
biallelic distribution of this polymorphism: alleles were grouped as
“low” (L) when the number of CA repeats was less than 21, and as
“high” (H) when the number of CA repeats was ≥21 [28].
Genotypes for the MMP-9 Q279R (rs17576) polymorphism were
determined by Taqman® Allele Discrimination assay. Probes and
primers used in theMMP-9 assaywere designed by Applied Biosystems
(ID: C_11655953_10). TaqMan polymerase chain reaction was
performed in a total volume of 12 μl (3 ng of DNA, 1× TaqMan master
mix, 900 nmol/l of each primer and 200 nmol/l of each probe) placed
in 96-well PCR plates. Fluorescence from polymerase chain reaction
ampliﬁcation was detected using Chromo 4 Detector (Bio-Rad Labora-
tories, Hercules, CA) and analyzed with the manufacturer's software
[23].
2.3. Measurement of plasma MMP-9 and TIMP-1 concentrations
The plasma MMP-9 and TIMP-1 concentrations were measured
with commercially available enzyme-linked immunosorbent assay
kits (DY911 and DY970, respectively; R&D Systems, Minneapolis,
MN, USA) according to the manufacturer's instructions.
2.4. Statistical analysis
Statistical analysis was carried out using the Stat-View (SAS
Institute, Cary, NC). The clinical characteristics, plasma MMP-9
and TIMP-1 concentrations, and MMP-9/TIMP-1 ratios were compared
with Student's paired t-test (parametric data), Mann–Whitney U-test
(non-parametric data) or chi-square (categorical data). The distribution
of genotypes for each polymorphism was assessed for deviation from
the Hardy–Weinberg equilibrium by using chi-squared tests. Difference
in the alleles, genotypes, and haplotype frequencies was assessed
with chi-squared tests. Because the TT genotype for the C−1562T
polymorphism was very rare, we combined this genotype with the
heterozygous CT genotype. A Pb0.05 was considered statistically
signiﬁcant.
The Bayesian statistical-based program Phase 2.1 was used to
estimate the haplotype frequencies in each group (http://depts.
washington.edu/uwc4c/express-licenses/assets/phase/). The possi-
ble haplotypes including genetic variants of three MMP-9 polymor-
phisms studied (C−1562T, 90(CA)14–24, and Q279R) were H1 (C, L,
Q); H2 (C, L, R); H3 (C, H, Q); H4 (C, H, R); H5 (T, L, Q); H6 (T, L, R);
H7 (T, H, Q); and H8 (T, H, R). Differences in haplotype frequency
distributions were further tested using contingency tables, and to
compare speciﬁc haplotype frequencies, a value of Pb0.01 (0.05/
number of observed haplotypes) was considered signiﬁcant to correct
for multiple comparisons. We excluded the rare haplotypes H5, H6
and H7 from the analysis.
3. Results
Clinical characteristics of patients are shown in Table 1. Detailed
information regarding the etiology of renal failure and coexistent
cardiovascular diseases and medications is provided in Supplementary
Table S1. The distribution of allele, genotype, and haplotype frequencies
in hemodialysis subjects are shown in Supplementary Table S2. The
distribution of genotypes for each polymorphism showed no deviation
from Hardy–Weinberg equilibrium (P>0.05).
The plasma MMP-9 and TIMP-1 concentrations were evaluated in
ESKD patients, both before and after hemodialysis. While the session
of hemodialysis increased MMP-9 and TIMP-1 plasma concentrations
(Fig. 1; P=0.0087 and P=0.0148, respectively), the MMP-9/TIMP-1
Table 1
Clinical and demographic characteristics of the patients.
Clinical characteristics Patients, N=94
Age, y 51±10.8
Race (white/non‐white) 79/15
Sex (masculine/feminine) 52/42
Smoking 44.39
SAP, mm Hg 141.4±40.3
DAP, mm Hg 78.8±12.5
Diabetes mellitus 34.6
Hypertension 79.6
BMI, kg/m2 25.29±5.18
Total cholesterol, mg/dl 157.8±54.6
HDL cholesterol, mg/dl 38.4±11.9
LDL cholesterol, mg/dl 86.6±40.9
Triglycerides, mg/dl 196.1±150.6
Hemoglobin, g/dl 10.4±2.8
Hematocrit, % 31.9±6.1
Leukocytes, ×103/μl 6518±2137
Creatinine, mg/dl 9.6±3.2
Calcium, mg/dl 8.8±1
Phosphorus, (mg/dl) 6.6±4.2
Potassium, (mg/dl) 5.2±1.2
PTH (pg/ml) 519.2±452
Albumin (mg/dl) 3.82±0.32
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found no signiﬁcant differences when patients with primary kidney
diseases and secondary kidney diseases were compared (data not
shown).
When ESKDpatientswere divided according to genotypes, we found
no signiﬁcant effects of genotypes on MMP-9 and TIMP-1 levels
measured before hemodialysis (Figs. 2, 3, and 4; all P>0.05). However,
hemodialysis increased MMP-9 levels in some genotype groups.
Speciﬁcally, we found signiﬁcant increases in both MMP-9 and
TIMP-1 levels in subjects with the CC genotype for the C−1562T
polymorphism (Fig. 2; both Pb0.05), but not in subjects with CT or
TT genotypes for this polymorphism. When the patients were divided
according the genotypes for the CA(n)14–24 polymorphism, we foundFig. 1. Effects of hemodialysis (HD) on the circulating MMP-9 and TIMP-1 concentrations and
in end stage kidney disease patients before (Pre HD) and after (Post HD) a session of HD. D
Fig. 2. Effects of hemodialysis (HD) on the circulating MMP-9 and TIMP-1 concentrations an
notypes for the MMP-9 C−1562T polymorphism. Concentrations of MMP-9, TIMP-1 and MM
are shown as mean±SD. *Statistically signiﬁcant.that TIMP-1 levels increased in subjects with the HH genotype (Fig. 3;
P=0.0375). However, this increase in TIMP-1 levels was not associated
with signiﬁcant changes in MMP-9/TIMP-1 ratios (Fig. 3; P>0.05).
Interestingly, we found a trend for increasedMMP-9 after hemodialysis
in subjects with the LL or the HL genotypes for this polymorphism
(Fig. 3; P=0.0668 and P=0.0730, respectively). When the patients
were divided according to genotypes for the Q279R polymorphism,
we found signiﬁcant increases in MMP-9 levels and in MMP-9/TIMP-1
ratios in subjects with the QQ genotype for this polymorphism (Fig. 4;
both Pb0.05). While we found signiﬁcant increases in TIMP-1 levels
in subjects with the QR genotype, this change was not associated with
signiﬁcant changes in MMP-9/TIMP-1 ratios (Fig. 4; P>0.05).
The analysis of haplotypes showed no effects of MMP-9 haplotypes
on both MMP-9 and TIMP-1 levels measured before hemodialysis
(Fig. 5; P>0.05). However, we found signiﬁcant increases in MMP-9
(but not TIMP-1) levels in subjects carrying the CLQ haplotype (Fig. 5;
P=0.0012), thus resulting in increased MMP-9/TIMP-1 ratio in this
particular haplotype group (Fig. 5; P=0.0045). While hemodialysis
was associated with increased TIMP-1 levels in subjects with the CHR
haplotype, no signiﬁcant changes were found in MMP-9/TIMP-1 ratio
(Fig. 5; P>0.05).
4. Discussion
This study examined howMMP-9 genetic polymorphisms affect the
changes in MMP-9 and TIMP-1 levels associated with a hemodialysis
session in ESKD patients. While we found that MMP-9 polymorphisms
do not signiﬁcantly affect baseline MMP-9 or TIMP-1 levels in ESKD
patients, we found a signiﬁcant genetic contribution of MMP-9
polymorphisms and haplotypes to hemodialysis-induced changes
in MMP-9 levels and MMP-9/TIMP-1 ratios. Our ﬁndings may help
to understand the relevance of MMP-9 genetic polymorphisms to
the pathophysiology of cardiovascular complications associated
with ESKD and hemodialysis.
MMPs (particularly MMP-9) are important for extracellular matrix
remodeling and play key roles in cardiovascular diseases [5,15,20,29].
MMP-9 activation promotes TGF-Β signaling and a sequence of eventsonMMP-9/TIMP-1 ratios. Concentrations of MMP-9, TIMP-1 andMMP-9/TIMP-1 ratios
ata are shown as mean±SD. *Statistically signiﬁcant.
d on MMP-9/TIMP-1 ratios in end stage kidney disease patients according to their ge-
P-9/TIMP-1 ratios are shown before (Pre HD) and after (Post HD) a session of HD. Data
Fig. 3. Effects of hemodialysis (HD) on the circulating MMP-9 and TIMP-1 concentrations and on MMP-9/TIMP-1 ratios in end stage kidney disease patients according to their ge-
notypes for the MMP-9 90(CA)14–24 polymorphism. Concentrations of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratios are shown before (Pre HD) and after (Post HD) a session of HD.
Data are shown as mean±SD. *Statistically signiﬁcant.
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recent studies showed that upregulated MMP-9, without proper
balance of TIMP-1, disrupts elastin and affects normal vascular
smooth muscle cells allowing the extracellular matrix to expand
and calcify, eventually leading to overt hydroxyapatite deposition
and vascular dysfunction [3,7,9].
Our results showing that hemodialysis elevated the circulating
levels of MMP-9 and TIMP-1 differ from previous reports, which
described reduced or unaltered MMP-9 and TIMP-1 levels after
hemodialysis [11,13,16,17]. We found minor increases in MMP-9/
TIMP-1 ratios, and this ﬁnding agrees with previous results [12].
It is likely that inconsistencies in reported plasma MMP levels
reﬂect the complex regulation of inﬂammation and MMPs, as well
as differences in sample size, populations, anticoagulation regimen,
vascular access, type of membrane and causal diseases for ESKD. In
addition, pre-analytical issues may also explain dissimilarities,
since modiﬁcations in processing the samples may alter MMP-9
levels [30,31]. MMP-9 is expressed constitutively at very low levels
in bone marrow-derived cells, however it is highly inducible under
oxidative and inﬂammatory conditions [6,10]. Since hemodialysis
activates inﬂammatory and coagulation pathways, it is plausible to
ﬁnd increased MMP-9 levels after hemodialysis.
MMP-9 gene polymorphisms may modify MMP-9 concentrations
and affect the development of cardiovascular complications in ESKD,
as previously suggested [1]. Indeed, the C−1562T polymorphism
results in loss of a nuclear repressor protein binding site and enhanced
MMP-9 mRNA and protein levels when the T allele is present [18,21].
The microsatellite 90(CA)14–24 in the promoter region of the MMP-9
gene was shown to reduce MMP-9 promoter activity when the (CA)
14 allele is present as compared with the (CA)21 allele [32]. The Q279R
polymorphism causes an aminoacid residue substitution, thus affectingFig. 4. Effects of hemodialysis (HD) on the circulating MMP-9 and TIMP-1 concentrations an
notypes for theMMP-9 Q−279R polymorphism. Concentrations of MMP-9, TIMP-1 and MMP-
shown as mean±SD. *Statistically signiﬁcant.MMP-9 activity [22,33]. Our results showing similar baseline MMP-9
and TIMP-1 levels suggest that these polymorphisms do not have
major effects in ESKD patients, at least in terms of circulating
MMP-9 levels.
We found that hemodialysis increased MMP-9 and TIMP-1 levels in
subjects with the CC (but not CT or TT) genotypes for the C−1562T poly-
morphism, and increased MMP-9 (but not TIMP-1) levels in subjects
with the QQ genotype for the Q279R polymorphism, thus increasing
MMP-9/TIMP-1 ratios. However, the haplotypic analysis may be much
more effective and informative than the single locus analysis [20].
While baseline MMP-9 and TIMP-1 levels were not affected by
MMP-9 haplotypes, subjects with the CLQ haplotype showed increased
MMP-9 (but not TIMP-1) levels after hemodialysis. Interestingly, this
particular haplotype combines the C allele for C−1562T polymorphism,
and L allele for the 90(CA)14–24 polymorphisms, which have been asso-
ciated with lower MMP-9 upregulation [18,21,32]. While we have not
examined the molecular mechanisms possibly explaining these ﬁnd-
ings, our results suggest that the CLQ haplotype combines a group of
MMP-9 genetic markers thatmay lead to the highest rates of cardiovas-
cular complications associated with abnormal MMP-9 activity in ESKD
patients undergoing hemodialysis. It remains to be determined wheth-
er MMP-9 inhibition is a suitable pharmacologic approach to prevent or
postpone cardiovascular in this highly susceptible population. In fact,
pharmacological blockade of MMPs has been suggested in hemodialysis
patients [4] and experimental evidence suggests that non-speciﬁc
MMP inhibition may prevent cardiovascular alterations through
complex mechanisms [34,35].
This study has some limitations that should be taken into consider-
ation. The ﬁndings reported here may be quantitatively small because
the differences that we found were not of major magnitude and some
of our ﬁndings may not resist correction for multiple comparisons.d on MMP-9/TIMP-1 ratios in end stage kidney disease patients according to their ge-
9/TIMP-1 ratios are shown before (Pre HD) and after (Post HD) a session of HD. Data are
Fig. 5. Effects of hemodialysis (HD) on the circulating MMP-9 and TIMP-1 concentrations and on MMP-9/TIMP-1 ratios in end stage kidney disease patients according to their
MMP-9 haplotypes. Concentrations of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratios are shown before (Pre HD) and after (Post HD) a session of HD. Data are shown as mean±SD.
*Statistically signiﬁcant.
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polymorphism to any clinical condition is usually of minor magnitude,
and our ﬁndings suggest that MMP-9 polymorphisms may have some
minor effects on MMP-9 changes induced by dialysis. Moreover,
the assays used in the present study are based on antigen detection
and may not reﬂect activity, particularly where a genotypic difference
may affect activity.
In conclusion, we found evidence supporting the idea that MMP
genetic polymorphisms affect MMP alterations in ESKD patients [25]
undergoing hemodialysis. ESKD patients with the QQ genotype for
the Q279R polymorphism or with the CLQ haplotype are exposed to
more severe increases in MMP-9 levels after hemodialysis. These
ﬁndings may indicate a group of patients that will have worse
cardiovascular prognosis when undergoing hemodialysis. Whether
such patients would beneﬁt from the use of MMP inhibitors remains
to be elucidated.
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